Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms
Metrics: HTML 914 views | ?
Zi-Xian Wang1,2,*, Lu-Ping Yang2,*, Miao-Zhen Qiu1,*, Zhi-Qiang Wang1,*, Yi-Xin Zhou3, Feng Wang1, Dong-Sheng Zhang1, Feng-Hua Wang1, Yu-Hong Li1, Rui-Hua Xu1
1Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2Faculty of Medical Sciences, Sun Yat-sen University, Guangzhou, China
3Department of VIP Region, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
*These authors have contributed equally to this study
Rui-Hua Xu, email: email@example.com
Keywords: gastric cancer, lactate dehydrogenase, D2 lymphadenectomy, prognosis, nomogram
Received: October 13, 2015 Accepted: April 2, 2016 Published: May 19, 2016
The present study aimed to evaluate the prognostic significance of preoperative serum lactate dehydrogenase (SLDH) levels for resected gastric cancer and construct prognostic nomograms for risk prediction. The study cohort consisted of 619 patients with D2-resected gastric cancer. The relationship of SLDH levels with clinicopathological features and clinical outcomes was evaluated. Prognostic nomograms were created using identified prognosticators to predict 3-year overall survival (OS) and 3-year disease-free survival (DFS), and bootstrap validation was performed. High SLDH levels were correlated with old age but not depth of invasion or lymph node metastasis. When assessed as a continuous variable, high SLDH levels were independently associated with poor OS and DFS. Internal validation of the developed nomograms revealed good predictive accuracy (bootstrap-corrected concordance indices: 0.77 and 0.75, respectively for prediction of OS and DFS). The preoperative SLDH levels, an identified unfavorable prognosticator, were incorporated into nomograms along with other clinicopathological features to refine the prediction of clinical outcomes for patients with D2-resected gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.